Citations

Clear

3314 citation(s) found for "Yu, Alexander".

Molecular Characterization and Therapeutic Opportunities in KRAS Wildtype Pancreatic Ductal Adenocarcinoma
Desai, Aakash , Xiao, Alexander , Toruner, Merih Deniz , Walden, Daniel , Hálfdánarson, Þorvarður R. , Mahipal, Amit , Ahn, Daniel H. , Stybayeva, Gulnaz , Revzin, Alexander , Kizilbash, Sani H. , Adjei, Alex A. , Bekaii‐Saab, Tanios , Mansfield, Aaron S. , Carr, Ryan M. , Xiao, Alexander H , Choi, Daheui , Toruner, Merih D , Halfdanarson, Thorvardur R , Alberts, Steven, Mahipal, Amit , Stybayeya, Gulnaz , Kizilbash, Sani, Mansfield, Aaron S , Carr, Ryan M , Desai, Aakash P , Bekaii-Saab, Tanios S , Kizilbash, Sani H , Alberts, Steven R. , McWilliams, Robert R. , Babiker, Hani M. , Wee, Wen

Mayo Clinic

Cancers | May 13, 2024 | Volume: 16 | Issue: 10 | Pages: 1861

10.3390/cancers16101861 | PMID 38791940 Get It

Purpose: To investigate the molecular characteristics of and potential for precision medicine in KRAS wildtype pancreatic ductal adenocarcinoma (PDAC). Patients and Methods: We investigated 27 patients with KRASWT PDAC at our institution. Clinical data were obtained via chart review. Tumor specimens for each subject were interrogated for somatic single nucleotide variants, insertion and deletions, and copy number variants by DNA sequencing. Gene fusions were detected from RNA-seq. A patient-derived organoid (PDO) was developed from a patient with a MET translocation and expanded ex vivo to predict therapeutic sensitivity prior to enrollment in a phase 2 clinical trial. Results: Transcriptomic analysis showed our cohort may be stratified by the relative gene expression of the KRAS signaling cascade. The PDO derived from our patient harboring a TFG-MET rearrangement was found to have in vitro sensitivity to the multi-tyrosine kinase inhibitor crizotinib. The patient was enrolled in the phase 2 SPARTA clinical trial and received monotherapy with vebrelitinib, a c-MET inhibitor, and achieved a partial and durable response. Conclusions: KRASWT PDAC is molecularly distinct from KRASMUT and enriched with potentially actionable genetic variants. In our study, transcriptomic profiling revealed that the KRAS signaling cascade may play a key role in KRASWT PDAC. Our report of a KRASWT PDAC patient with TFG-MET rearrangement who responded to a cMET inhibitor further supports the pursuit of precision oncology in this sub-population. Identification of targetable mutations, perhaps through approaches like RNA-seq, can help enable precision-driven approaches to select optimal treatment based on tumor characteristics.
Evaluating the Ability of Brachial Plexus-Injured Patients to Control an Externally Powered (Myoelectric) Hand Prosthesis
Lee, Ellen Y. , NELSON, A. WENDELL , Sampson, Brandon P. , Smither, F. Clay , Pulos, Nicholas , Bishop, Allen T. , Spinner, Robert J. , Shin, Alexander Y. , Shin, Alexander Y , Bishop, Allen T , Pulos, Nicholas

Mayo Clinic

Journal of Bone and Joint Surgery | May 10, 2024 | Volume: 106 | Issue: 24 | Pages: 2375-2382

10.2106/jbjs.23.00938 | PMID 38728379 Get It

Background: Restoration of hand function after traumatic brachial plexus injury (BPI) remains a formidable challenge. Traditional methods such as nerve or free muscle transfers yield suboptimal results. Advancements in myoelectric prostheses, characterized by novel signal acquisition and improved material technology, show promise in restoring functional grasp. This study evaluated the ability of adults with a BPI injury to control an externally powered prosthetic hand using nonintuitive signals, simulating the restoration of grasp with a myoelectric prosthesis. It also assessed the effectiveness of a comprehensive multidisciplinary evaluation in guiding treatment decisions. Methods: A multidisciplinary brachial plexus team assessed adults with compromised hand function due to BPI. The feasibility of amputation coupled with fitting of a myoelectric prosthesis for grasp reconstruction was evaluated. Participants' ability to control a virtual or model prosthetic hand using surface electromyography (EMG) as well as with contralateral shoulder motion-activated linear transducer signals was tested. The patient’s input and injury type, along with the information from the prosthetic evaluation, were used to determine the reconstructive plan. The study also reviewed the number of participants opting for amputation and a myoelectric prosthetic hand for grasp restoration, and a follow-up survey was conducted to assess the impact of the initial evaluation on decision-making. Results: Of 58 subjects evaluated, 47 (81%) had pan-plexus BPI and 42 (72%) received their initial assessment within 1 year post-injury. Forty-seven patients (81%) could control the virtual or model prosthetic hand using nonintuitive surface EMG signals, and all 58 could control it with contralateral uniscapular motion via a linear transducer and harness. Thirty patients (52%) chose and pursued amputation, and 20 (34%) actively used a myoelectric prosthesis for grasp. The initial evaluation was informative and beneficial for the majority of the patients, especially in demonstrating the functionality of the myoelectric prosthesis. Conclusions: The study indicates that adults with traumatic BPI can effectively operate a virtual or model myoelectric prosthesis using nonintuitive control signals. The simulation and multidisciplinary evaluation influenced informed treatment choices, with a high percentage of patients continuing to use the myoelectric prostheses post-amputation, highlighting its long-term acceptance and viability. Level of Evidence: Therapeutic Level IV . See Instructions for Authors for a complete description of levels of evidence.
Utilizing median and maximum QTc values improves prediction of breakthrough cardiac events in pediatric long QT syndrome
Rohatgi, Ram K., Tseng, Andrew S. , Sugrue, Alan , Lee, Alexander T. , Wackel, Phillip L., Cannon, Bryan C. , Bos, J. Martijn , Ackerman, Michael J. , Sugrue, Alan , Wackel, Philip , Ackerman, Michael J , Tseng, A S , Bos, Johan M , Scott, Christopher G.

Mayo Clinic

Journal of Cardiovascular Electrophysiology | May 10, 2024 | Volume: 35 | Issue: 7 | Pages: 1370-1381

10.1111/jce.16293 | PMID 38725227 Get It

AbstractIntroductionAlthough prior studies indicate that a QTc > 500 ms on a single baseline 12‐lead electrocardiogram (ECG) is associated with significantly increased risk of arrhythmic events in long QT syndrome (LQTS), less is known about the risk of persistent QT prolongation. We sought to determine QTc persistence and its prognostic effect on breakthrough cardiac events (BCEs) among pediatric patients treated for LQTS.MethodsWe performed a retrospective analysis of 433 patients with LQTS evaluated, risk‐stratified, and undergoing active guideline‐based LQTS treatment between 1999 and 2019. BCEs were defined as arrhythmogenic syncope/seizure, sudden cardiac arrest (SCA), appropriate VF‐terminating ICD shock, and sudden cardiac death (SCD).ResultsDuring the median follow‐up of 5.5 years (interquartile range [IQR] = 3–9), 32 (7%) patients experienced a total of 129 BCEs. A maximum QTc threshold of 520 ms and median QTc threshold of 490 ms were determined to be strong predictors for BCEs. A landmark analysis controlling for age, sex, genotype, and symptomatic status demonstrated models utilizing both the median QTc and maximum QTc demonstrated the highest discriminatory value (c‐statistic = 0.93–0.95). Patients in the high‐risk group (median QTc > 490 ms and maximum QTc > 520 ms) had a significantly lower BCE free survival (70%–81%) when compared to patients in both medium‐risk (93%–97%) and low‐risk (98%–99%) groups.ConclusionsThe risk of BCE among patients treated for LQTS increases not only based upon their maximum QTc, but also their median QTc (persistence of QTc prolongation). Patients with a maximum QTc > 520 ms and median QTc > 490 ms over serial 12‐lead ECGs are at the highest risk of BCE while on guideline‐directed medical therapy.
Secukinumab in adult patients with lichen planus: efficacy and safety results from the randomized placebo-controlled proof-of-concept PRELUDE study
Reinhardt, Maximilian, Ehst, Benjamin D. , Weiss, Jonathan , Sluzevich, Jason C. , Reygagne, Pascal , Wohlrab, Johannes , Fazel, Nasim , Muscianisi, Elisa , Fan, Heng , Hampele, Isabelle, Compagno, Nicolò , Sluzevich, Jason, Sluzevich, Jason C , Passeron, Thierry , Sticherling, Michael , Hertl, Michael

Mayo Clinic

British Journal of Dermatology | May 9, 2024 | Volume: 191 | Issue: 5 | Pages: 680-690

10.1093/bjd/ljae181 | PMID 38735684 Get It

Abstract Background Patients with lichen planus (LP) refractory to available therapies often experience a high disease burden, representing a population with a clear unmet need for new treatments. Objectives To evaluate the efficacy and safety of secukinumab 300 mg over 32 weeks in adult patients with biopsy-proven cutaneous LP (CLP), mucosal LP (MLP) or lichen planopilaris (LPP) that is inadequately controlled by topical corticosteroids. Methods PRELUDE was a randomized double-blind placebo-controlled phase II proof-of-concept study that enrolled patients with CLP, MLP or LPP. Eligible patients were randomized to either secukinumab 300 mg every 4 weeks for 32 weeks (SECQ4W) or placebo for 16 weeks followed by secukinumab 300 mg every 2 weeks (SECQ2W) for 16 weeks. The primary endpoint was achievement of the newly designed Investigator’s Global Assessment (IGA) score ≤ 2 at week 16. Results Overall, 111 patients were randomized (n = 37 each) to CLP, MLP and LPP cohorts. As the proof-of-concept criteria were not met for any of the three cohorts, the primary objective was not met. A numerically higher proportion of patients achieved IGA ≤ 2 response at week 16 with SECQ4W vs. placebo in the MLP {37.5% [95% credibility interval (Crl) 20.3–57.2] vs. 23.1% (95% Crl 6.5–49.2)} and LPP cohorts [37.5% (95% Crl 20.2–57.3) vs. 30.8% (95% Crl 10.8–57.6)]. In the LPP cohort, a sustained response for IGA ≤ 2 from week 16 to week 32 was achieved with SECQ4W (week 16, 37.5%; week 32, 45.8%), and a substantial improvement was observed in IGA ≤ 2 response in patients from this cohort who switched from placebo (week 16, 30.8%) to SECQ2W after week 16 (week 32, 63.6%). The safety profile was consistent with the known profile of secukinumab and showed no new or unexpected signals. Conclusions PRELUDE is the first randomized controlled basket trial evaluating interleukin (IL)-17A inhibition with secukinumab across three subtypes of LP. Secukinumab was well tolerated and safe, showing different response rates across the three subtypes, with numerical IGA improvements in MLP and LPP, and no response in CLP. The study raises the question of a differential role of IL-17A across LP subtypes. The novel IGA score showed significant correlation with both patient- and physician-reported outcome measurements.
Listening to patients, for the patients: The COVAD Study—Vision, organizational structure, and challenges
Joshi, Mrudula , Darooka, Naitica , Saha, Sreoshy , Dyball, Sarah , Sen, Parikshit , Yaadav, Praggya , Javaid, Mahnoor , Kadam, Esha , Shinjo, Samuel Katsuyuki , Dey, Dzifa , Gutiérrez, Carlos Enrique Toro , Caballero‐Uribe, Carlo V. , Kuwana, Masataka , Burmester, Gerd R , Ziadé, Nelly , Wincup, Chris , Parodis, Ioannis , Tan, Ai Lyn , Wang, Guochun , Dalbeth, Nicola , Velikova, Tsvetelina , Nikiphorou, Elena , Agarwal, Vikas , Gupta, Latika, group, the COVAD study, Tehozol, Erick Adrian Zamora , Alpizar-Rodriguez, D. , Singla, Shikha , Cheng, Karen Kow Yip , Gupta, Latika , Cavagna, Lorenzo , Makol, Ashima , Gutiérrez, Carlos Enrique Toro , Caballero-Uribe, Carlo Vinicio , Kuwana, Masataka , Burmester, Gerd-Rüdiger , Ziade, Nelly , Wincup, Chris , Andreoli, Laura , Parodis, Ioannis , Tan, Ai Lyn , Guillemin, Francis , Knitza, Johannes , Wang, Guochun , Dalbeth, Nicola , Velikova, Tsvetelina , Gracia-Ramos, Abraham Edgar , Nikiphorou, Elena , Day, Jessica , Chinoy, Hector , Aggarwal, Rohit , Agarwal, Vikas , Gupta, Latika , Joshi, Mrudula , Shinjo, Samuel Katsuyuki , Alpízar-Rodríguez, Deshiré , Zamora Tehozol, Erick Adrian , Dey, Dzifa , Sen, Parikshit , Saha, Sreoshy , Darooka, Naitica , Yaadav, Praggya , Cheng, Karen , Kadam, Esha , Makol, Ashima , Andréoli, Laura , Gracia‐Ramos, Abraham Edgar , Day, Jessica , Chinoy, Hector , Aggarwal, Rohit , group, the COVAD study

Mayo Clinic

International Journal of Rheumatic Diseases | May 9, 2024 | Volume: 27 | Issue: 5 | Pages: No page available

10.1111/1756-185x.15161 | PMID 38720408 Get It

AbstractBackgroundThe pandemic presented unique challenges for individuals with autoimmune and rheumatic diseases (AIRDs) due to their underlying condition, the effects of immunosuppressive treatments, and increased vaccine hesitancy.ObjectivesThe COVID‐19 vaccination in autoimmune diseases (COVAD) study, a series of ongoing, patient self‐reported surveys were conceived with the vision of being a unique tool to gather patient perspectives on AIRDs. It involved a multinational, multicenter collaborative effort amidst a global lockdown.MethodsLeveraging social media as a research tool, COVAD collected data using validated patient‐reported outcomes (PROs). The study, comprising a core team, steering committee, and global collaborators, facilitated data collection and analysis. A pilot‐tested, validated survey, featuring questions regarding COVID‐19 infection, vaccination and outcomes, patient demographics, and PROs was circulated to patients with AIRDs and healthy controls (HCs).DiscussionWe present the challenges encountered during this international collaborative project, including coordination, data management, funding constraints, language barriers, and authorship concerns, while highlighting the measures taken to address them.ConclusionCollaborative virtual models offer a dynamic new frontier in medical research and are vital to studying rare diseases. The COVAD study demonstrates the potential of online platforms for conducting large‐scale, patient‐focused research and underscores the importance of integrating patient perspective into clinical care. Care of patients is our central motivation, and it is essential to recognize their voices as equal stakeholders and valued partners in the study of the conditions that affect them.
Cardiac biomarkers for diagnosing Takotsubo syndrome
Schweiger, Victor , Vece, Davide Di , Cammann, Victoria L. , Koleva, Iva, Würdinger, Michael , Gilhofer, Thomas , Rajman, Katja, Szawan, Konrad A. , Niederseer, David , Gili, Sebastiano , Franke, Jennifer , Meder, Benjamin , Knorr, Maike, Jansen, Thomas , Bruno, Francesco , Filippo, Ovidio De , Stefanini, Giulio , Wańha, Wojciech , Lewinski, Dirk von , Burgdorf, Christof , Kherad, Behrouz , Tschöpe, Carsten , Sarcon, Annahita, Shinbane, Jerold S., Rajan, Lawrence, Michels, Guido, Pfister, Roman , Jacobshagen, Claudius, Karakas, Mahir , Pott, Alexander , Meyer, Philippe , Roffi, Marco , Wolfrum, Mathias , Fischer, Thomas, Vasankari, Tuija , Dworakowski, Rafał , MacCarthy, Philip , Osswald, Stefan , Galiuto, Leonarda , Chan, Christina , Bridgman, Paul , Beug, Daniel , Gilyarova, Ekaterina, Poledníková, Karolína, Massoomi, Michael , Carrilho‐Ferreira, Pedro , Hauck, Christian , Paolini, Carla , Bilato, Claudio , Kobayashi, Yoshio , Ishibashi, Iwao, Himi, Toshiharu, Din, Jehangir , Rihal, Charanjit S. , Jörg, Lucas, Rickli, Hans , Böhm, Michael , Pinto, Fausto J. , Widimský, Petr , Felix, Stephan B. , Rottbauer, Wolfgang , Budnik, Monika , Opolski, Grzegorz , Kong, William , Dalakoti, Mayank , Imori, Yoichi , Münzel, Thomas , Lüscher, Thomas F. , Ghadri, Jelena R. , Templin, Christian , Citro, Rodolfo , Vecchione, Carmine , Bossone, Eduardo , Meder, Benjamin , Bruno, Francesco , De Filippo, Ovidio , Campo, Gianluca , von Lewinski, Dirk , Tschöpe, Carsten , Pfister, Roman , Koenig, Wolfgang , Meyer, Philippe , Banning, Adrian , Kobza, Richard , Galiuto, Leonarda , Lairez, Olivier , Gilyarov, Mikhail , Akin, Ibrahim , Ukena, Christian , Hauck, Christian , Paolini, Carla , Bilato, Claudio , Böhm, Michael , Widimský, Petr , Rottbauer, Wolfgang , Schunkert, Heribert , Thiele, Holger , Bauersachs, Johann , Di Mario, Carlo , Bax, Jeroen J , Templin, Christian , Koleva, Iva, Citro, Rodolfo , Vecchione, Carmine , Bossone, Eduardo , Neuhaus, Michael, Jaguszewski, Miłosz , Noutsias, Michel , D’Ascenzo, Fabrizio , Campo, Gianluca , Raposeiras‐Roubín, Sergio , Dichtl, Wolfgang , Cuneo, Alessandro , Köenig, Wolfgang , Banning, Adrian , Cuculi, Florim , Kobza, Richard , Airaksinen, Juhani , Napp, L. Christian , Kaiser, Christoph A. , Delmas, Clément , Lairez, Olivier , Shilova, Alexandra S. , El‐Battrawy, Ibrahim , Toušek, Petr , Winchester, David E. , Gałuszka, Jan , Ukena, Christian , Poglajen, Gregor , Kato, Ken , Al‐Shammari, Ali Saad , Prasad, Abhiram , Rihal, Charanjit S. , Liu, Kan , Schulze, Paul Christian , Bianco, Matteo , Pestana, Gonçalo , Nguyen, Thanh Ha Tuan , Maier, Lars S. , Braun-Dullaeus, Ruediger Christian , Hasenfuß, Gerd , Pieske, Burkert , Horowitz, John D. , Mario, Carlo Di , Bax, Jeroen J. , Crea, Filippo , Ruschitzka, Frank T.

Mayo Clinic

European Heart Journal | May 8, 2024 | Volume: 45 | Issue: 25 | Pages: 2254-2258

10.1093/eurheartj/ehae231 | PMID 38717630 Get It

Volumetric Analysis of a Novel Chimeric Gracilis and Profunda Artery Perforator Flap
Spronsen, Nicole Van , Plonkowski, Alexander T. , Jokerst, Clint , Shrout, Max A., Reece, Edward, Casey, William J., Rebecca, Alanna M. , Van Spronsen, Nicole R, Reece, Edward M., Hammond, Jacob B. , Flug, Jonathan A.

Mayo Clinic

Journal of Reconstructive Microsurgery | May 6, 2024 | Volume: 41 | Issue: 01 | Pages: 063-067

10.1055/a-2320-5489 | PMID 38710225 Get It

Abstract Background The presence of a chimeric gracilis and profunda artery perforator (PAP) flap with a common arterial pedicle has been demonstrated on computed tomography angiography in up to 59% of patients and confirmed in a cadaveric model. Already utilized for head and neck reconstruction by Heredero et al, this novel flap could provide more volume than either flap alone which is advantageous, particularly in patients with sizable defects. The purpose of this study was to determine the average tissue volume that can be utilized from this chimeric flap. Methods CT Angiogram imaging studies exhibiting chimeric flap anatomy were reviewed over a 7-year period at a single institution utilizing Visage Version 7.1, a radiology picture archiving and communication system. This software was used to trace the flap pedicles and to capture estimated soft tissue volumes of each respective flap. Results A total of 31 patients, consisting of 52 lower extremity gracilis and PAP chimeric flaps, underwent tissue volume analysis. The average total volume of soft tissue supplied by the gracilis flap was found to be 70.21 cm3 (standard deviation [SD] = 26.99). The average volume of the PAP flap was 31.73 cm3 (SD = 26.12). The average total volume captured by the chimeric gracilis and PAP flap was 101.94 cm3 (SD = 62.40). Conclusion The potential soft tissue volume that can be harvested from a chimeric gracilis and PAP flap is significantly greater than solitary gracilis or PAP flaps. This chimeric flap may serve as a viable and advantageous reconstructive option for patients requiring large volume soft tissue coverage, particularly if other sizable options are not available.
Clinical validation of C 12 FDG as a marker associated with senescence and osteoarthritic phenotypes
Hambright, William S. , Duke, Victoria R. , Goff, Adam D., Goff, Alex W., Minas, Lucas T., Kloser, Heidi , Huard, Charles, Guo, Ping , Lu, Aiping , Mitchell, John M., Netto, Jair Machado Espindola, Niedernhofer, Laura J. , Kirkland, James L. , Bahney, Chelsea S. , Huard, Johnny , Lu, Aiping , Tchkonia, Tamara, Espindola Netto, Jair M , Robbins, Paul D , Niedernhofer, Laura J , Bahney, Chelsea S , Philippon, Marc , Huard, Johnny , Duke, Victoria , Goff, Alexander , Gao, Xueqin , Mitchell, John, Mullen, Michael T. , Su, Charles A. , Tchkonia, Tamar , Espíndola‐Netto, Jair Machado , Robbins, Paul D. , Philippon, Marc J.

Mayo Clinic

Aging Cell | May 6, 2024 | Volume: 23 | Issue: 5 | Pages: No page available

10.1111/acel.14113 | PMID 38708778 Get It

Abstract Chronic conditions associated with aging have proven difficult to prevent or treat. Senescence is a cell fate defined by loss of proliferative capacity and the development of a pro‐inflammatory senescence‐associated secretory phenotype comprised of cytokines/chemokines, proteases, and other factors that promotes age‐related diseases. Specifically, an increase in senescent peripheral blood mononuclear cells (PBMCs), including T cells, is associated with conditions like frailty, rheumatoid arthritis, and bone loss. However, it is unknown if the percentage of senescent PBMCs associated with age‐associated orthopedic decline could be used for potential diagnostic or prognostic use in orthopedics. Here, we report senescent cell detection using the fluorescent compound C 12 FDG to quantify PBMCs senescence across a large cohort of healthy and osteoarthritic patients. There is an increase in the percent of circulating C 12 FDG + PBMCs that is commensurate with increases in age and senescence‐related serum biomarkers. Interestingly, C 12 FDG + PBMCs and T cells also were found to be elevated in patients with mild to moderate osteoarthritis, a progressive joint disease that is strongly associated with inflammation. The percent of C 12 FDG + PBMCs and age‐related serum biomarkers were decreased in a small subgroup of study participants taking the senolytic drug fisetin. These results demonstrate quantifiable measurements in a large group of participants that could create a composite score of healthy aging sensitive enough to detect changes following senolytic therapy and may predict age‐related orthopedic decline. Detection of peripheral senescence in PBMCs and subsets using C 12 FDG may be clinically useful for quantifying cellular senescence and determining how and if it plays a pathological role in osteoarthritic progression.
Abstract PO1-01-01: ECOG-ACRIN EA1211: Interim FDG-PET/CT for predicting response of HER2-positive breast cancer to neoadjuvant therapy (DIRECT Trial)
Jacene, Heather A. , Gatsonis, Constantine, Connolly, Roisín M. , Burnette, Brian L., Stringer-Reasor, Erica , Hennessy, Maeve, Taurone, Alexander, O’Sullivan, Ciara C. , Le‐Petross, Huong T. , Sepulveda, Karla A., Mankoff, David A. , Mankoff, David A , Romanoff, Justin , Lawhn-Heath, Courtney A. , Stearns, Vered , Fowler, Amy M. , Tang, Shou-Ching , DeMichele, Angela , Wolff, Antonio C.

Mayo Clinic

Cancer Research | May 2, 2024 | Volume: 84 | Issue: 9_Supplement | Pages: PO1-01-01-PO1-01-01

10.1158/1538-7445.sabcs23-po1-01-01 Get It

Abstract Background: Strategies to optimize treatment decision-making in early stage HER2-positive breast cancer are a current priority for the oncology and patient advocacy community. Recent studies suggest that early metabolic changes on FDG-PET/CT (imaging biomarker) predict response to HER2-directed therapy. The TBCRC026 trial showed that participants not obtaining a 40% reduction in SULmax by cycle 1 day 15 (C1D15) following neoadjuvant trastuzumab/pertuzumab (HP) were unlikely to obtain pCR [negative predictive value (NPV) 91%]. The ECOG-ACRIN EA1211/DIRECT trial aims to validate FDG-PET/CT as a neoadjuvant interim (niFDG-PET/CT) imaging integral biomarker in patients treated with standard HER2-directed regimens (NCT05710328). Design: EA1211/DIRECT is a multicenter, single-arm, primary imaging phase 2 study enrolling patients with stage II/III HER2-positive breast cancer. Patients undergo standard skull base-thigh FDG-PET/CT at baseline and C1D15 and receive standard of care pertuzumab-based neoadjuvant therapy followed by surgery. Eligibility: Age ≥18 years, ECOG performance status 0-2, stage IIa-IIIc, untreated HER2-positive breast cancer with known hormone receptor status, suitable to undergo FDG-PET/CT imaging and neoadjuvant therapy. Methods: ΔSULmaxD15 will be computed as: (D15 SULmax – baseline SULmax)/baseline SULmax. The primary objective is to estimate the NPV of niFDG-PET/CT for pCR using ΔSULmaxD15 of the primary breast cancer at a threshold of 40%, in patients treated with neoadjuvant HER2-directed therapy. NPV is defined as the probability that pCR will not be achieved by participants with ΔSULmaxD15 < 40%. Secondary endpoints include evaluating the sensitivity, specificity, and positive predictive value of ΔSULmaxD15 of the primary breast cancer at a threshold of 40% and the ability of the niFDG-PET/CT biomarker to predict 3-year event free survival (EFS). Sample Size: We expect that 50% of patients will not reach the ΔSULmax threshold of 40% and a pCR rate of 40-60%. The proposed sample size is 210 participants, adjusted to 235 to account for missing data in 10% of cases. Computation of exact, two-sided 95% confidence intervals (CI) for NPV determined the lower limit of the CI is at least 80% when the true NPV is at least 88%. The lower limit is 84% when the true NPV has the value of 91%, which was estimated in the TBCRC026 study. Current Status: EA1211/DIRECT was activated in May 2023 across the NCI National Clinical Trials Network (NCTN), and accrual is anticipated to complete in March 2025. Those interested in the clinical trial can email ea1211team@ecog-acrin.org. Conclusion: The EA1211/DIRECT trial is the first step in implementing a Response-Guided Treatment Strategy by validating the ΔSULmax threshold of 40% as the optimum cut point across standard of care HER2-directed neoadjuvant regimens. If EA1211/DIRECT meets its objectives, the results will be used to design clinical utility studies, and thus hoping to change practice. Citation Format: Heather Jacene, Constantine Gatsonis, Roisin Connolly, Brian Burnette, Erica Stringer-Reasor, Maeve Hennessy, Justin Romanoff, Alexander Taurone, Ciara O'Sullivan, H. T. Carisa Le-Petross, Courtney Lawhn Heath, Vered Stearns, Amy Fowler, Shou-Ching Tang, Karla A Sepulveda, Angela DeMichele, David Mankoff, Antonio Wolff. ECOG-ACRIN EA1211: Interim FDG-PET/CT for predicting response of HER2-positive breast cancer to neoadjuvant therapy (DIRECT Trial) [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr PO1-01-01.